In summary, in HIV+ persons with severe hemophilia A, the use of very high-purity (monoclonally purified) factor VIII concentrates was associated with stabilization of absolute CD4+ cell counts over 3 years. The use of intermediate-purity concentrates (specific activity ≤50 U/mg) was associated with deterioration of absolute CD4+ cell counts over time. However, there was a statistically significant difference in time to two consecutive CD4+ cell counts + cell count will result in improved clinical outcome. These data provide a rationale for selecting very high-purity factor VIII for HIV+ hemophiliacs.
|Journal||AIDS Patient Care|
|Issue number||SUPPL. 1|
|Publication status||Published - 1994|
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Leadership and Management